Unsealed documents detail Biogen's fight against Sandoz Tysabri biosimilar

Sandoz is hoping to celebrate its recently announced spinoff from Novartis with swift approvals for its Tysabri biosimilar in both the US and Europe — but not if Biogen can help it.

Biogen filed suit against Sandoz earlier this month, accusing the company of attempting to “reap the benefits of Biogen’s hard work and success” by allegedly infringing on Tysabri’s patent rights.